GSK completes $3 billion acquisition of Human Genome
LONDON (Reuters) - GlaxoSmithKline has completed its $3 billion acquisition of long-time biotech partner Human Genome Sciences, after buying all the outstanding shares for $14.25 each in cash, Britain's biggest drugmaker said on Friday.
The deal secures it full rights to recently launched lupus drug Benlysta and other experimental medicines.
(Reporting by Ben Hirschler)
NEW YORK - U.S. stocks were set to open slightly lower on Monday, on the heels of a record high for the S&P 500, following unexpectedly weak data in China which tempered enthusiasm over the strength of the global economy. | Video
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.